Abstract
Background
Medullary thyroid carcinoma (MTC) is a malignant tumour derived from the para-follicular thyroid C cells. It may occur in sporadic or hereditary forms and surgery represent the primary cure.
Methods
Ultrasound examination and, in selected cases, cross-sectional anatomic imaging procedures, are adopted to stage the disease before primary surgery while different anatomic/morphologic and functional/molecular imaging procedures can be adopted in detecting persistent/recurrent disease. Positron emitting radiopharmaceuticals including fluorine-18 fluorodeoxyglucose (18F-FDG), fluorine-18 dihydroxyphenylalanine (18F-FDOPA) and somatostatin analogues labelled with gallium-68 (68Ga-SSA) tracks different metabolic pathways or receptor expression/functioning, and proved to be useful in detecting MTC recurrences/metastasis.
Conclusions
This practice guideline from the Thyroid Committee of the European Association of Nuclear Medicine (EANM), with involvement of external experts, provides recommendations based on updated literature’s evidences. The purpose of this practice guideline is to assist imaging specialists and clinicians in recommending, performing and interpreting the results of PET/CT with various radiopharmaceuticals in patients with MTC.
Similar content being viewed by others
References
Trimboli P, Giovanella L, Crescenzi A, Romanelli F, Valabrega S, Spriano G, et al. Medullary thyroid cancer diagnosis: an appraisal. Head Neck. 2014;36:1216–23.
Guyetant S, Rousselet MC, Durigon M, Chappard D, Franc B, Guerin O, et al. Sex-related C-cell hyperplasia in the normal human thyroid: a quantitative autopsy study. J Clin Endocrinol Metab. 1997;82:42–7.
Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458–60.
Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994;367:375–6.
Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL, et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol. 1996;44:249–57.
Boichard A, Croux L, Al Ghuzlan A, Broutin S, Dupuy C, Leboulleux S, et al. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab. 2012;97:E2031–5.
Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab. 2013;98:E364–9.
Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol. 2004;61:299–310.
Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg. 2002;26:22–8.
Moley JF. Medullary thyroid carcinoma: management of lymph node metastases. J Natl Compr Cancer Netw. 2010;8:549–56.
Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC study group. Groupe d’etude des tumeurs a calcitonine. Clin Endocrinol. 1998;48:265–73.
Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610.
Trimboli P, Seregni E, Treglia G, Alevizaki M, Giovanella L. Procalcitonin for detecting medullary thyroid carcinoma: a systematic review. Endocr Relat Cancer. 2015;22:R157–64.
Trimboli P, Giovanella L. Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature. Clin Chem Lab Med. 2015;53:1507–14.
Trimboli P, Treglia G, Guidobaldi L, Romanelli F, Nigri G, Valabrega S, et al. Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. Clin Endocrinol. 2015;82:280–5.
Trimboli P, Guidobaldi L, Bongiovanni M, Crescenzi A, Alevizaki M, Giovanella L. Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: a systematic review. Diagn Cytopathol. 2016;44:45–51.
Chernock RD, Hagemann IS. Molecular pathology of hereditary and sporadic medullary thyroid carcinomas. Am J Clin Pathol. 2015;143:768–77.
Khurana R, Agarwal A, Bajpai VK, Verma N, Sharma AK, Gupta RP, et al. Unraveling the amyloid associated with human medullary thyroid carcinoma. Endocrinology. 2004;145:5465–70.
Mendelsohn G, Wells SA Jr, Baylin SB. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease. Cancer. 1984;54:657–62.
Trimboli P, Giovanella L, Valabrega S, Andrioli M, Baldelli R, Cremonini N, et al. Ultrasound features of medullary thyroid carcinoma correlate with cancer aggressiveness: a retrospective multicenter study. J Exp Clin Cancer Res. 2014;33:87.
Skoura E. Depicting medullary thyroid cancer recurrence: the past and the future of nuclear medicine imaging. Int J Endocrinol Metab. 2013;11:e8156.
Rufini V, Castaldi P, Treglia G, Perotti G, Gross MD, Al-Nahhas A, et al. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother. 2008;62:139–46.
Clarke SE, Lazarus CR, Wraight P, Sampson C, Maisey MN. Pentavalent [99mTc]DMSA, [131I]MIBG, and [99mTc]MDP–an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med. 1988;29:33–8.
Frank-Raue K, Bihl H, Dorr U, Buhr H, Ziegler R, Raue F. Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol. 1995;42:31–7.
Kwekkeboom DJ, Reubi JC, Lamberts SW, Bruining HA, Mulder AH, Oei HY, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab. 1993;76:1413–7.
Verga U, Muratori F, Di Sacco G, Banfi F, Libroia A. The role of radiopharmaceuticals MIBG and (V) DMSA in the diagnosis of medullary thyroid carcinoma. Henry Ford Hosp Med J. 1989;37:175–7.
Ozkan ZG, Kuyumcu S, Uzum AK, Gecer MF, Ozel S, Aral F, et al. Comparison of 68Ga-DOTATATE PET-CT, 18F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. Nucl Med Commun. 2015;36:242–50.
Arslan N, Ilgan S, Yuksel D, Serdengecti M, Bulakbasi N, Ugur O, et al. Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery. Clin Nucl Med. 2001;26:683–8.
Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med. 1996;37:912–6.
Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab. 2001;86:895–902.
Maiza JC, Grunenwald S, Otal P, Vezzosi D, Bennet A, Caron P. Use of 131 IMIBG therapy in MIBG-positive metastatic medullary thyroid carcinoma. Thyroid. 2012;22:654–5.
Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92:4185–90.
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–54.
Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44(9):1588–601.
Treglia G, Castaldi P, Villani MF, Perotti G, Filice A, Ambrosini V, et al. Comparison of different positron emission tomography tracers in patients with recurrent medullary thyroid carcinoma: our experience and a review of the literature. Recent Results Cancer Res. 2013;194:385–93.
Treglia G, Muoio B, Giovanella L, Salvatori M. The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview. Eur Arch Otorhinolaryngol. 2013;270:1783–7.
Treglia G, Giovanella L, Rufini V. PET and PET/CT imaging in thyroid and adrenal diseases: an update. Hormones. 2013;12:327–33.
Treglia G, Rufini V, Salvatori M, Giordano A, Giovanella L. PET imaging in recurrent medullary thyroid carcinoma. Int J Mol Imaging. 2012;2012:324686.
Rufini V, Treglia G, Perotti G, Leccisotti L, Calcagni ML, Rubello D. Role of PET in medullary thyroid carcinoma. Minerva Endocrinol. 2008;33:67–73.
Soussan M, Nataf V, Kerrou K, Grahek D, Pascal O, Talbot JN, et al. Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nucl Med Commun. 2012;33(7):775–9.
Treglia G, Stefanelli A, Castaldi P, Rufini V. A standardized dual-phase 18F-DOPA PET/CT protocol in the detection of medullary thyroid cancer. Nucl Med Commun. 2013;34(2):185–6.
Chondrogiannis S, Marzola MC, Al-Nahhas A, Venkatanarayana TD, Mazza A, Opocher G, et al. Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging. Nucl Med Commun. 2013;34(12):1141–9.
Chondrogiannis S, Grassetto G, Marzola MC, Rampin L, Massaro A, Bellan E, et al. 18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours. Nucl Med Commun. 2012;33(2):179–84.
Treglia G, Cocciolillo F, Di Nardo F, Poscia A, de Waure C, Giordano A, et al. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis. Acad Radiol. 2012;19(10):1290–9.
Treglia G, Tamburello A, Giovanella L. Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis. Hormones (Athens). 2017;16(4):262–72.
Traub-Weidinger T, Putzer D, von Guggenberg E, Dobrozemsky G, Nilica B, Kendler D, et al. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism. Eur J Nucl Med Mol Imaging. 2015;42(13):1995–2001.
Bodet-Milin C, Faivre-Chauvet A, Carlier T, Rauscher A, Bourgeois M, Cerato E, et al. Immuno-PET using anticarcinoembryonic antigen bispecific antibody and 68Ga-labeled peptide in metastatic medullary thyroid carcinoma: clinical optimization of the Pretargeting parameters in a first-in-human trial. J Nucl Med. 2016;57(10):1505–11.
Ong SC, Schöder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gönen M, et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med. 2007;48(4):501–7.
Werner RA, Schmid JS, Higuchi T, Javadi MS, Rowe SP, Märkl B, et al. Predictive value of FDG-PET in patients with advanced medullary thyroid carcinoma treated with vandetanib. J Nucl Med. 2018;59(5):756–61.
Romero-Lluch AR, Cuenca-Cuenca JI, Guerrero-Vázquez R, Martínez-Ortega AJ, Tirado-Hospital JL, Borrego-Dorado I, et al. Diagnostic utility of PET/CT with (18)F-DOPA and (18)F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff. Eur J Nucl Med Mol Imaging. 2017;44(12):2004–13.
Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, et al. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide. Eur J Nucl Med Mol Imaging. 2013;40(3):364–72.
Łapińska G, Bryszewska M, Fijołek-Warszewska A, Kozłowicz-Gudzińska I, Ochman P, Sackiewicz-Słaby A. The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours. Nucl Med Rev Cent East Eur. 2011;14(1):16–20.
Pałyga I, Kowalska A, Gąsior-Perczak D, Tarnawska-Pierścińska M, Słuszniak J, Sygut J, et al. The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (68Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC). Endokrynol Pol. 2010;61(5):507–11.
Golubić AT, Pasini Nemir E, Žuvić M, Mutvar A, Kusačić Kuna S, Despot M, et al. The value of 18F-DOPA PET/CT in patients with medullary thyroid carcinoma and increased calcitonin values. Nucl Med Commun. 2017;38(7):636–41.
Archier A, Heimburger C, Guerin C, Morange I, Palazzo FF, Henry JF, et al. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2016;43(6):1027–33.
Gómez-Camarero P, Ortiz-de Tena A, Borrego-Dorado I, Vázquez-Albertino RJ, Navarro-González E, Ruiz-Franco-Baux JV, et al. Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test. Rev Esp Med Nucl Imagen Mol. 2012;31(5):261–6.
Skoura E, Rondogianni P, Alevizaki M, Tzanela M, Tsagarakis S, Piaditis G, et al. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer. Nucl Med Commun. 2010;31(6):567–75.
Rasul S, Hartenbach S, Rebhan K, Göllner A, Karanikas G, Mayerhoefer M, et al. [18F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery. EurJ Nucl Med Mol Imaging. 2018;45(12):2159–69.
Treglia G, Villani MF, Giordano A, Rufini V. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine. 2012;42:535–45.
Kauhanen S, Schalin-Jäntti C, Seppänen M, Kajander S, Virtanen S, Schildt J, et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J Nucl Med. 2011;52(12):1855–63.
Ozkan E, Soydal C, Kucuk ON, Ibis E, Erbay G. Impact of 18F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma. Nucl Med Commun. 2011;32(12):1162–8.
Jang HW, Choi JY, Lee JI, Kim HK, Shin HW, Shin JH, et al. Localization of medullary thyroid carcinoma after surgery using (11)C-methionine PET/CT: comparison with (18)F-FDG PET/CT. Endocr J. 2010;57(12):1045–54.
Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16(21):5260–8.
Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010;28(14):2323–30.
Skoura E, Rondogianni P, Alevizaki M, Tzanela M, Tsagarakis S, Piaditis G, et al. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer. Nucl Med Commun. 2010;31(6):567–75.
Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, et al. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol. 2010;36(4):414–21.
Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, et al. The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma. Mol Imaging Biol. 2010;12(5):547–53.
Beheshti M, Pöcher S, Vali R, Waldenberger P, Broinger G, Nader M, et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol. 2009;19(6):1425–34.
Rubello D, Rampin L, Nanni C, Banti E, Ferdeghini M, Fanti S, et al. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study. Eur J Surg Oncol. 2008;34(5):581–6.
Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab. 2007;92(12):4590–7.
Ong SC, Schöder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gönen M, et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med. 2007;48(4):501–7.
Caobelli F, Chiaravalloti A, Evangelista L, Saladini G, Schillaci O, Vadrucci M, et al. Young AIMN Working Group. Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid. Ann Nucl Med. 2018;32(1):7–15.
Sesti A, Mayerhoefer M, Weber M, Anner P, Wadsak W, Dudczak R et al. Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-flurodihydroxyphenylalanine PET. Anticancer res 2014;34:6647–54.
Treglia G, Aktolun C, Chiti A, Frangos S, Giovanella L, Hoffmann M, et al. EANM and the EANM thyroid committee. The 2015 revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of nuclear medicine. Eur J Nucl Med Mol Imaging. 2016;43(8):1486–90.
Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010;20(5):527–33.
Soussan M, Nataf V, Kerrou K, Grahek D, Pascal O, Talbot JN, et al. Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nucl Med Commun. 2012;33(7):775–9.
Yamaga LYI, Cunha ML, Campos Neto GC, Garcia MRT, Yang JH, Camacho CP, et al. (68)Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with (111)In-octreotide SPECT/CT and conventional imaging. Eur J Nucl Med Mol Imaging. 2017;44(10):1695–701.
Budiawan H, Salavati A, Kulkarni HR, Baum RP. Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)yttrium and (177)lutetium labeled somatostatin analogs: toxicity, response and survival analysis. Am J Nucl Med Mol Imaging. 2013;4(1):39–52.
Tran K, Khan S, Taghizadehasl M, Palazzo F, Frilling A, Todd JF, et al. Gallium-68 dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin. Hell J Nucl Med. 2015;18(1):19–24.
Acknowledgements
This practice guideline summarizes the views of EANM Thyroid Committee and produces recommendations for which the EANM cannot be considered responsible. The recommendations should be adopted in the context of good nuclear medicine practice of nuclear and do not substitute national and international regulations. Before approval, this practice guideline was available to all EANM Committees and EANM National Societies of Nuclear Medicine. All comments, criticisms and suggestions have been considered for this EANM practice guideline.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
L.G. is member of Roche Diagnostics advisory board and received research grants and speaker fees from Roche Diagnostics, IBSA and Sanofi-Genzyme. F.A.V. has received research grants from Sanofi-Genzyme and speaker honoraria from Sanofi-Genzyme, Diasorin and Jubilant Draximage. M.L. has received research grants and speaker honoraria from Sanofi-Genzyme, Bayer and Astra Zeneca. G.T declares that he has no conflict of interest. I.I declares that he has no conflict of interest. JM declares that she has no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Oncology – Head and Neck
Rights and permissions
About this article
Cite this article
Giovanella, L., Treglia, G., Iakovou, I. et al. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 47, 61–77 (2020). https://doi.org/10.1007/s00259-019-04458-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-019-04458-6